Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Investment Tools And Research To Help Make You A More Confident And Profitable Trader. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Kinnate Biopharma Inc (KNTE)

Kinnate Biopharma Inc (KNTE)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Kinnate Biopharma Inc. Sells Its Investigational Pan-RAF Inhibitor, exarafenib, to Pierre Fabre Laboratories Newswire.ca - Fri Mar 1, 2024

Kinnate has entered into an Asset Purchase Agreement (the "APA") with Pierre Fabre Laboratories for global rights to exarafenib and other pan-RAF program...

KNTE : 2.65 (-0.38%)
Wall Street - shutterstock_1321462394
S&P Futures Plunge Ahead of FOMC Meeting, Oil’s Climb Raises Inflation Concerns Barchart - Tue Sep 19, 2023

December S&P 500 futures (ESZ23) are trending down -0.51% this morning as market participants geared up for a big week for central banks, with the spotlight on the Federal Reserve’s interest rate decision...

AYX : 48.26 (+0.02%)
AAPL : 281.74 (-0.72%)
KGF.LN : 287.900 (-1.07%)
TSLA : 411.84 (+8.46%)
GMED : 83.94 (-2.68%)
NIO : 4.95 (+1.85%)
KNTE : 2.65 (-0.38%)
PLNT : 51.58 (-2.20%)
ARM : 343.58 (+2.79%)
ESZ23 : 4,694.27s (-0.58%)
DELL : 414.61 (+3.78%)
AVGR : 0.4740 (-20.74%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029 FinancialNewsMedia - Thu Jun 1, 2023

EQNX::TICKER_START (NASDAQ:KTTA),(NASDAQ:SWTX),(NASDAQ:DAWN),(NASDAQ:VSTM),(NASDAQ:KNTE) EQNX::TICKER_END

KTTA : 0.5261 (-3.18%)
KNTE : 2.65 (-0.38%)
DAWN : 21.53 (+0.19%)
VSTM : 3.82 (+1.06%)
SWTX : 46.99 (+0.02%)
Neurofibromatosis Treatment Market Value Expected to Reach $27 Billion By End Of 2029 PR Newswire - Thu Jun 1, 2023

/PRNewswire/ -- Neurofibromatosis is a genetic condition that disrupts the cell growth in your nervous system, causing formation of tumors on nerve tissue....

KTTA : 0.5261 (-3.18%)
KNTE : 2.65 (-0.38%)
DAWN : 21.53 (+0.19%)
VSTM : 3.82 (+1.06%)
SWTX : 46.99 (+0.02%)

Barchart Exclusives

This Lesser-Known Dividend Stock Is Beating the S&P 500 in 2026 and Yields More Than 3% Barchart - Mon Jun 29, 6:30PM CDT
Watsco has raised its quarterly dividend by 10% to $3.30 per share, lifting the annualized payout to $13.20 and delivering a forward yield above 3%. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.